New drug launch: Ensidipine latest price announced in 2024

Enasidenib is an oral small molecule drug primarily used to treat a specific type of leukemia called acute myeloid leukemia (AML). AML is a malignant tumor that affects stem cells in the bone marrow and blood, causing the production of abnormal white blood cells.

Ensidipine has not yet obtained marketing approval in China, which means that domestic patients cannot purchase the drug directly and must purchase it through overseas channels. Abroad, relatively low-priced drug options are generic drugs, especially those produced in Laos and Bangladesh, which sell for between 2,000 and 4,000 yuan. It is worth mentioning that these generic drugs are very close to the original drugs in terms of pharmaceutical ingredients.

Ensidipine is an inhibitor of isomeric cysteine synthase2 (IDH2). IDH2 is an enzyme involved in cellular energy metabolism and redox processes. In some AML patients, IDH2 gene mutations will lead to an abnormal increase in IDH2 enzyme activity, producing a A metabolite called 2-hydroxyglutarate (2-HG), which in turn promotes the abnormal proliferation and survival of AML cells.

Ensidipine blocks the production of 2-HG by inhibiting IDH2enzyme activity, thus interfering with the abnormal metabolic pathways of AML cells and inhibiting their proliferation and survival. This specific effect on AML cells makes ensidipine a promising targeted therapy.

In clinical trials, ensidipine has been shown to have significant therapeutic effects in AML patients carrying IDH2 gene mutations. Studies have shown that ensidipine can significantly reduce the number of abnormal white blood cells in AML patients, extend their progression-free survival, improve survival rates, and cause relatively few toxic side effects associated with traditional chemotherapy.

When using ensidipine, patients usually take it orally once a day at a dose of 100mg (mg). It is recommended to take it after meals. The treatment cycle is 28 days, and patients need to continue taking the drug until the doctor determines the time to stop taking the drug.

Although ensidipine has shown good efficacy and safety in the treatment ofAML, it may also cause some side effects, such as gastrointestinal discomfort, abnormal liver function, bone marrow suppression, etc. Therefore, during treatment, patients need to be regularly monitored and evaluated by doctors to ensure the effectiveness and safety of the treatment.